Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary quantitative data synthesis
PubMed 34690504 · doi:10.1177/11795514211051697
What was done
This narrative review synthesized literature examining the hypoglycemic effects and general adverse effect profile of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes and healthy individuals, along with related regulatory safety evaluations.
What was found
The abstract reports no quantitative data or numerical effect sizes. It qualitatively reports that GLP-1 receptor agonists have been proposed to cause hypoglycemia in healthy normoglycemic subjects, contrary to the assumption of strictly glucose-dependent action, while other studies found risk depends on individual factors. It also notes that the FDA evaluated potential safety signals across 12 marketed GLP-1 receptor agonists.
Why it matters
The paper synthesizes evidence questioning the assumption that GLP-1 receptor agonists carry negligible hypoglycemia risk, highlighting possible glucose-independent pathways and patient-specific risk factors.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The abstract provides no sample sizes, incidence rates, or effect sizes, and does not specify which individual agents or combination therapies were evaluated.
Cited by
- supports In non-diabetics, blood sugar levels do not drop very low when taking GLP-1 receptor agonists.